Navigation Links
Enox Biopharma, Inc. Grants TTA LTD License To Wound Care Applications
Date:6/26/2012

VANCOUVER, British Columbia, June 26, 2012 /PRNewswire/ -- Enox Biopharma, Inc. (VANCOUVER, BC.), a leader in the development of innovative solutions for infections associated with medical devices and TTA LTD (Tel Aviv, Israel) today announced an execution of an exclusive royalty bearing license agreement under which Enox Biopharma shall grant TTA LTD rights to patent application and knowhow for use in developing novel therapies for wound care applications.

Under this agreement, Enox Biopharma assigned a recently filed provisional patent to TTA that covers novel means of delivering nitric oxide directly to wounds. Nitric oxide is well known in its ability to both prevent infections and act as a vasodilator which increases blood flow. Both of these are beneficial during the wound healing process. Direct exposure of a wound to nitric oxide has promise to facilitate the closing of chronic wounds that would not otherwise heal. TTA will use Enox Biopharma's innovation to develop innovative wound healing treatments and technologies. 

"This agreement allows for concurrent focused development at Enox of our core competency and technology related to rendering medical devices antimicrobial and at TTA of wound care applications," said John Rewcastle, Enox's CEO. "Both these are significant endeavors that require company focus. I have the utmost confidence that TTA will be successful in their efforts which will, of course, be beneficial to Enox."

Racheli Vizman, TTA LTD's COO commented, "The wound care market is massive and expected to exceed twenty billion dollars by 2015. Unfortunately for patients today the market is also underserved. We believe the technology developed by Enox has very significant potential to revolutionize the wound care field. TTA will be working to take the technology through the development and regulatory process."

About Enox Biopharma, Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into polymers. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. Enox's device technology is applicable to any indwelling polymer medical device including, but not limited to, catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide.

About TTA, LTD.

TTA Ltd. is a privately held, Israel-based company focuses on developing innovative topical therapeutics products for wound healing. 

For more information, please contact:

John C. Rewcastle, Ph.D, CEO or
Itamar David, CFO
Enox Biopharma, Inc.
604.637.9744 phone
888.224.7259 fax
info@enoxbiopharma.com
www.enoxbiopharma.com

TTA contact information:

Racheli  Vizman,COO
TTA, LTD.
Tel: +972-52-5659922
Fax: +972-3-9233228
Email: Racheli.vizman@gmail.com


'/>"/>
SOURCE Enox Biopharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Enox Biopharma, Inc. Will Present at IN360 Investment in Innovation Conference
2. Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry
3. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
4. Maryland Stem Cell Research Commission Announces New Program for Pre-Clinical and Clinical Research Grants
5. NSF CAREER grants support ocean energy, microforming, computer planning
6. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
7. FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
8. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
9. ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes - Expected Launch in Q2 2012
10. HistoRx Licenses Melanoma Assay from Yale University
11. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... NEW YORK , February 4, 2016 ... (OTCQB: QBIO), a biotechnology acceleration company is pleased to provide ... --> --> Over the last 3 months ... note and securities purchase agreements exceeding $1,000,000. As a result, ... under our Mannin Research Inc. license agreement and expect that ...
(Date:2/4/2016)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property ... intellectual property, today provided an update on the Company,s ... of Texas and announcing that ... Partes Re-examination ("IPR") proceedings that VTech and Uniden ... initiated on only certain claims of two of the ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... supplier of Semantic Graph Database technology has been recognized As “ Best in ... Corporate America Magazine. , “At Corporate America, it’s our priority to showcase prominent ...
(Date:2/4/2016)... ... 2016 , ... Many of the engineers at FireflySci, Inc. have been manufacturing ... apart from other cuvette manufacturers is their supercharged customer service and their extensive database ... this steady flow of inside information, they have recently revamped their manufacturing techniques to ...
Breaking Biology Technology:
(Date:1/15/2016)... , Jan. 15, 2016 Recent publicized ... small to find new ways to ensure data security ... iOS and Android that ties ... biometrics, transforming it into a hardware authorization token. Customer ... swipe their fingerprint on their KodeKey enabled device to ...
(Date:1/11/2016)... JOSE, Calif. , Jan. 11, 2016 ... of human interface solutions, today announced that its ClearPad ... driver integration (TDDI) products won two separate categories in ... Best Mobile Innovator and Best Technology Breakthrough. The Synaptics ... system cost, a simplified supply chain, thinner devices, brighter ...
(Date:1/8/2016)... January 8, 2016 NXTD ), ... WorldVentures ® , a privately held leading direct seller ... Inc. 5000 fastest-growing company announced that on December ... $2 million in Nxt-ID to develop a proprietary new ... Wocket ® , a unique smart wallet that serves ...
Breaking Biology News(10 mins):